264 results on '"Sanmarti, Raimon"'
Search Results
2. Complete disappearance of pulmonary rheumatoid nodules after long term rituximab treatment: case report
3. Neutrophils, neutrophil extracellular traps, and rheumatoid arthritis: An updated review for clinicians
4. Neutrófilos, trampas extracelulares de neutrófilos y artritis reumatoide: una revisión actualizada para clínicos
5. Rheumatoid arthritis: extra articular manifestations and comorbidities
6. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis
7. Palindromic rheumatism: Evidence of four subtypes of palindromic-like arthritis based in either MEFV or rheumatoid factor/ACPA status
8. Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study
9. Neutrophilic Activity Biomarkers (Plasma Neutrophil Extracellular Traps and Calprotectin) in Established Patients with Rheumatoid Arthritis Receiving Biological or JAK Inhibitors: A Clinical and Ultrasonographic Study
10. Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis
11. Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure
12. Efficacy and safety of combined therapy with synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: Systematic literature review
13. Aspectos prácticos de la medición de los niveles de fármacos biológicos y de anticuerpos antifármaco en artritis reumatoide y espondiloartritis
14. Eficacia y seguridad de la terapia combinada con fármacos modificadores de la enfermedad sintéticos en la artritis reumatoide: revisión sistemática de la literatura
15. Expert recommendations on the interleukin 6 blockade in patients with rheumatoid arthritis
16. Recomendaciones de experto sobre el bloqueo de la interleucina 6 en pacientes con artritis reumatoide
17. Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review
18. Eficacia y seguridad de los glucocorticoides en la artritis reumatoide: revisión sistemática de la literatura
19. Assessing treatment tolerability for rheumatoid arthritis. Validation and practical applications of the ‘TOL-AR-18 questionnaire’
20. A Composite Indicator to Assess the Quality of Care in the Management of Patients With Rheumatoid Arthritis in Outpatient Rheumatology Clinics
21. Indicador compuesto para evaluar la calidad asistencial en el manejo de los pacientes con artritis reumatoide en las consultas externas de Reumatología
22. Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring in Clinical Practice: The Spanish Cohort of the COMORA Study
23. Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences aboutUBA1mosaicism
24. Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases
25. Recomendaciones sobre el uso de metrotexato parenteral en enfermedades reumáticas
26. REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients
27. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project
28. Variability in Rheumatology Day Care Hospitals in Spain: VALORA Study
29. Variabilidad en los hospitales de día de Reumatología en España: proyecto VALORA
30. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
31. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study
32. 2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis
33. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide
34. Efficacy and Safety of Golimumab as Add-on Therapy to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the GO-MORE Study in Spain
35. Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España
36. Seronegative palindromic rheumatism: what are we talking about? Comment on the article by Yang et al
37. Complete disappearance of pulmonary rheumatoid nodules after long term rituximab treatment: case report
38. Reduction of Biological Agent Dose in Rheumatic Diseases: Descriptive Analysis of 153 Patients in Clinical Practice Conditions
39. Reducción de dosis de terapias biológicas en enfermedades reumáticas: análisis descriptivo de 153 pacientes en condiciones de práctica clínica
40. Musculoskeletal Involvement in Hereditary Hemochromatosis
41. How do Spanish Rheumatologists handle referral? Survey of knowledge and approach before and after a training workshop
42. ¿Cómo manejan la remisión los reumatólogos españoles? Encuesta de conocimientos y abordaje antes y después de un taller formativo
43. Model of Excellence in Rheumatology Day Hospitals in Spain: The HD-Reumatolex Project
44. Modelo de excelencia en el Hospital de Día de Reumatología en España: proyecto HD-Reumatolex
45. Skin Lesions and Treatment With Tumor Necrosis Factor Alpha Antagonists
46. Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations
47. El uso de abatacept en artritis reumatoide: revisión de la evidencia y recomendaciones
48. Lesiones cutáneas y terapia biológica con antagonistas del factor de necrosis tumoral
49. Tobacco and Other Environmental Risk Factors in Rheumatoid Arthritis
50. Tabaco y otros factores ambientales en la artritis reumatoide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.